All IndicationsOncologyApprovedApprovedPhase 1
🎗️
oncology
8
Companies
9
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
PFE
Pfizer
palbociclib
RHHBY
Roche
Ziihera
BLRX
BioLineRx Ltd.
GLIX1
7827
HanchorBio, Inc.
HCB101
LEGN
Legend Biotech
PD-1xVEGF bispecific
MRK
Merck
Lipfendra
CIPLA
Cipla Limited
Pembrolizumab
AMGN
Amgen
Imdelltra
RHHBY
Roche
ivonescimab
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| PFE Pfizer | palbociclib | Approved | — | — | — |
| RHHBY Roche | Ziihera | Approved | — | — | — |
| BLRX BioLineRx Ltd. | GLIX1 | Phase 1 | — | — | — |
| 7827 HanchorBio, Inc. | HCB101 | — | — | — | — |
| LEGN Legend Biotech | PD-1xVEGF bispecific | — | — | — | — |
| MRK Merck | Lipfendra | — | — | — | — |
| CIPLA Cipla Limited | Pembrolizumab | — | — | — | — |
| AMGN Amgen | Imdelltra | — | — | — | — |
| RHHBY Roche | ivonescimab | — | — | — | — |
Development Stage Distribution
Unknown
6
Approved
2
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.